Model-based development of anacetrapib, a novel cholesteryl ester transfer protein inhibitor

AAPS Journal

Volumn 13, Issue 2, 2011, Pages 179-190

  Krishna, Rajesh ^a   Bergman, Arthur J ^a   Green, Michele ^b   Dockendorf, Marissa F ^a   Wagner, John A ^a   Dykstra, Kevin ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b CERTARA   (United States)

Author keywords

anacetrapib; cetp inhibition; clinical trial simulation; modeling

Indexed keywords

ANACETRAPIB; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG POTENTIATION; DYSLIPIDEMIA; HUMAN; LOW FAT DIET; MAJOR CLINICAL STUDY; MEAL; MONOTHERAPY; POPULATION MODEL; STATISTICAL MODEL; TABLET FORMULATION; VOLUNTEER;

ANTICHOLESTEREMIC AGENTS; BIOLOGICAL AVAILABILITY; CAPSULES; CHOLESTEROL ESTER TRANSFER PROTEINS; COMPUTER SIMULATION; DIET, FAT-RESTRICTED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG INTERACTIONS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; OXAZOLIDINONES; PYRROLES; TABLETS;

EID: 79957463739     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-011-9254-0     Document Type: Article

References (9)

1. R Krishna MS Anderson AJ Bergman B Jin M Fallon J Cote K Rosko C Chavez-Eng R Lutz D Bloomfield M Gutierrez J Doherty F Bieberdorf J Chodakewitz KM Gottesdiener JA Wagner 2007 Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomized placebo-controlled phase I studies Lancet 370 1907 14 18068514 10.1016/S0140-6736(07)61813-3 1:CAS:528:DC%2BD2sXhsVShtLrE (Pubitemid 350192656)
2. R Krishna AJ Bergman B Jin M Fallon J Cote P Van Hoydonck T Laethem IN Gendrano K Van Dyck DA Hilliard OF Laterza KM Snyder CM Chavez-Eng R Lutz J Chen DM Bloomfield M De Smet L Van Bortel M Gutierrez N Al-Huniti K Dykstra KM Gottesdiener JA Wagner 2008 Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects Clin Pharmacol Ther 84 6 679 83 18580870 10.1038/clpt.2008.109 1:CAS:528:DC%2BD1cXhtlOjtrzI
3. D Bloomfield GL Carlson A Sapre D Tribble JM McKenney TW Littlejohn 3rd CM Sisk Y Mitchel RC Pasternak 2009 Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients Am Heart J 157 2 352 60 19185645 10.1016/j.ahj.2008.09.022 1:CAS:528:DC%2BD1MXhtlSkt7w%3D
4. R Krishna A Garg B Jin J Cote A Bergman P Von Hoydonck T Laethem K Van Dyck C Chavez-Eng L Archer R Lutz D Hilliard K Snyder D Panebianco L Bortel K Lasseter N Al-Huniti K Dykstra K Gottesdiener JA Wagner 2009 Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects Br J Clin Pharmacol 68 4 535 45 19843057 10.1111/j.1365-2125.2009.03465.x 1:CAS:528:DC%2BD1MXhsVyis73J
5. Sheiner LB, Beal SL. NONMEM Users Guide. San Francisco: Division of Pharmacology, University of California; 1979.
6. JW Mandema D Hermann W Wang T Sheiner M Milad R Bakker-Arkema D Hartman 2005 Model-based development of gemcabene, a novel lipid altering agent AAPS J 7 3 E513 22 16353929 10.1208/aapsj070352 (Pubitemid 41631737)
7. RW Clark TA Sutfin RB Suggeri AT Willauer ED Sugarman G Magnus-Aryitey PG Cosgrove TM Sand RT Wester JA Williams ME Perlman MJ Bamberger 2004 Raising high-density lipoprotein in humans through inhibition of cholestryl ester transfer protein: an initial multidose study of torceterapib Aterioscler Thromb Vasc Biol 24 490 7 10.1161/01.ATV.0000118278.21719.17 1:CAS:528: DC%2BD2cXhvFOis7c%3D (Pubitemid 38326143)
8. CP Cannon HM Dansky M Davidson AM Gotto Jr EA Brinton AL Gould M Stepanavage SX Liu S Shah J Rubino P Gibbons A Hermanowski-Vosatka B Binkowitz Y Mitchel P Barter 2009 DEFINE investigators. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib Am Heart J 158 4 513 519 19781408 10.1016/j.ahj.2009.07.028 1:CAS:528: DC%2BD1MXhtFyjsr3L
9. CP Cannon S Shah H Dansky M Davidson E Brinton AM Gotto Jr M Stepanavage SX Liu P Gibbons TB Ashraf J Zafarino Y Mitchel P Barter 2010 Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 25 2406 2415 10.1056/NEJMoa1009744 21082868 10.1056/NEJMoa1009744 1:CAS:528:DC%2BC3cXhsF2ltLfL